C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway

Oncology Letters

Volumn 3, Issue 2, 2012, Pages 395-400

  Zhang, Lingyun ^a   Teng, Yuee ^a   Zhang, Ye ^a   Liu, Jing ^a   Xu, Ling ^a   Qu, Jinglei ^a   Hou, Kezuo ^a   Yang, Xianghong ^a   Liu, Yunpeng ^a   Qu, Xiujuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; C Src; Migration; Receptor activator for nuclear factor B ligand

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B;

ARTICLE; BREAST CANCER; CELL MIGRATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84855224166     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.487     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
3. Moore MA: The role of chemoattraction in cancer metastases. Bioessays 23: 674-676, 2001.
4. Jones DH, Nakashima T, Sanchez OH, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696, 2006.
5. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
6. Yasuda H, Shima N, Nakagawa N, et al: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602, 1998.
7. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
8. Keller ET: The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 38: 91-102, 2002.
9. Thomas RJ, Guise TA, Yin JJ, et al: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458, 1999.
10. Hsu H, Lacey DL, Dunstan CR, et al: Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540-3545, 1999.
11. Nakagawa N, Kinosaki M, Yamaguchi K, et al: RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253: 395-400, 1998.
12. Mikami S, Katsube K, Oya M, et al: Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218: 530-539, 2009.
13. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104, 2008.
14. Chen LM, Kuo CH, Lai TY, et al: RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J Cell Biochem 112: 933-941, 2011.
15. Santini D, Perrone G, Roato I, et al: Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 226: 780-784, 2011.
16. Hiscox S, Jordan NJ, Morgan L, Green TP and Nicholson RI: Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 24: 157-167, 2007.
17. Meng XN, Jin Y, Yu Y, et al: Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 101: 327-334, 2009.
18. Summy JM and Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22: 337-358, 2003.
19. Sabbota AL, Kim HRC, Zhe X, Fridman R, Bonfil RD and Cher ML: Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res 70: 5558-5566, 2010.
20. Myoui A, Nishimura R, Williams PJ, et al: c-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 63: 5028-5033, 2003.
21. Zhang XH, Wang Q, Gerald W, et al: Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16: 67-78, 2009.
22. Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG and Schutte M: Low-risk susceptibility alleles in 40 human breast cancer cell lines. BMC Cancer 9: 236, 2009.
23. Kenny P, Lee G, Myers C, et al: The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1: 84-96, 2007.
24. Gan Y, Shi C, Inge L, Hibner M, Balducci J and Huang Y: Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 29: 4947-4958, 2010.
25. Jiang Q, Zhou C, Bi Z and Wan Y: EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells. J Ocul Pharmacol Ther 22: 93-102, 2006.
26. Hwang YP, Yun HJ, Choi JH, et al: Suppression of EGF-induced tumor cell migration and matrix metalloproteinase-9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK, p38 MAPK, and AP-1 signaling. Mol Nutr Food Res 55: 594-605, 2011.
27. Darnay BG, Haridas V, Ni J, Moore PA and Aggarwal BB: Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kB and c-Jun N-terminal kinase. J Biol Chem 273: 20551-20555, 1998.
28. Chen T and Feng X: Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors. Assay Drug Dev Technol 4: 473-482, 2006.
29. Darnay BG, Ni J, Moore PA and Aggarwal BB: Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274: 7724-7731, 1999.
30. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC and Choi Y: TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity 7: 703-713, 1997.
31. Santini D, Schiavon G, Vincenzi B, et al: Receptor activator of NF-κB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 6: e19234, 2011.
32. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813-822, 2011.
33. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132-5139, 2010.
34. Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437, 2007.
35. Rifkin WD: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 2390-2391; author reply 2390-2391, 2006.
36. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN and Ueno NT: Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 7: 641-651, 2010.
37. Mayer EL and Krop IE: Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 16: 3526-3532, 2010.
38. Araujo J and Logothetis C: Targeting Src signaling in metastatic bone disease. Int J Cancer 124: 1-6, 2009.
39. Saad F and Lipton A: SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 36: 177-184, 2010.